Metformin, but not sitagliptin, enhances WP 631-induced apoptotic HepG2 cell death

摘要: Metformin and sitagliptin are hypoglycemic drugs with potential use in cancer treatment. Evidence indicates that metformin may inhibit the proliferation growth of various types cells. Data regarding relationship between cells is limited. Therapy based on anthracycline derivatives, mainly doxorubicin, commonly used treatment resistant liver cancers. WP 631 a new structural analogue doxorubicin exerts an anticancer action by induction apoptosis. The aim this study was to compare effect 631-induced apoptotic cell death human hepatocarcinoma line (HepG2). HepG2 known be chemotherapeutic cytotoxic agents. Both MTT assay flow cytometry analysis showed reduced apoptosis induction, accompanied elevated NF-κB p53 levels. enhanced pro-apoptotic 631, increasing level but not level. Sitagliptin did affect cells, however, it increased To conclude, our results suggest significantly enhances efficacy derivative, although observed case sitagliptin. Therefore, seems good candidate for combined therapy derivatives.